Stock Analysis
Canopy Growth Second Quarter 2025 Earnings: Misses Expectations
Canopy Growth (TSE:WEED) Second Quarter 2025 Results
Key Financial Results
- Revenue: CA$63.0m (down 9.5% from 2Q 2024).
- Net loss: CA$131.6m (loss narrowed by 1.4% from 2Q 2024).
- CA$1.52 loss per share (improved from CA$1.86 loss in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Canopy Growth Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) also missed analyst estimates by 192%.
Looking ahead, revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada.
Performance of the Canadian Pharmaceuticals industry.
The company's shares are down 13% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 3 warning signs for Canopy Growth you should be aware of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSX:WEED
Canopy Growth
Engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally.